Marex Group Limited (MRX) Analyst Forecast
Revenue and earnings estimates published by analysts covering Marex Group Limited (MRX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Marex Group Limited, analysts forecast revenue rising from $1555.64T in 2024 to $16771.01T in 2029; the average estimate for 2029 earnings per share is $10.45; with published estimates ranging from $9.08 to $11.09; 6 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD millions)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Marex Group Limited (MRX) forecast — frequently asked questions
What is the analyst price target for Marex Group Limited?
Analysts covering Marex Group Limited (MRX) have a consensus price target of $83.67, 18.3% above the current price of $70.73. Published targets range from $80.00 to $92.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Marex Group Limited's earnings?
The average analyst estimate for Marex Group Limited (MRX) earnings per share in 2029 is 10.45, with individual estimates between 9.08 and 11.09.
How much revenue is Marex Group Limited expected to make?
Analysts forecast Marex Group Limited (MRX) revenue of $16771.01T in 2029, based on 3 published estimates.
How many analysts cover MRX?
6 analysts contribute estimates for Marex Group Limited (MRX). Thin coverage makes an average less reliable.
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.